For the first time, UK vets are now able to offer the only veterinarian-administered single-dose treatment for canine otitis externa (OE).

Neptra® ear solution for dogs is the latest innovation from Bayer Animal Health – providing anti-inflammatory, anti-fungal and anti-bacterial activity – the product is now available for veterinarians to prescribe in routine OE cases.

The UK launch follows a highly successful launch in the USA, under a different name, Claro. Claro is now the number one product for otitis externa in the country, with over 4.7 million doses prescribed by veterinarians since 2017.[i]

“This solution is trusted by thousands of vets across the USA, it’s now time for UK vets to benefit from the convenience and confidence Neptra® offers. Neptra® is the ideal and easier way to treat the majority of otitis externa cases you see and can (and should) be used first-line,” explains Dr Ken Kwochka, DVM, DACVD, President of the World Association for Veterinary Dermatology.

Containing a unique combination of active ingredients, Neptra^® is effective against the most common bacterial and fungal pathogens** - associated with 70-80% of OE cases. Clinical trials have demonstrated Neptra’s lasting efficacy, showing continuous clinical improvement until day 28 with just one dose.

Neptra^® contains:

Florfenicol - An established first-line antibiotic, this provides potent antibacterial activity

Florfenicol is an excellent first-line antibiotic with strong gram-positive activity, making it an ideal choice for vets to deal with Staphylococcus pseudintermedius found in the majority of otitis externa cases.

Terbinafine hydrochloride - Provides potent anti-yeast activity, highly effective against Malassezia pachydermatis.

Mometasone furoate – A highly lipophilic corticosteroid that provides powerful anti-inflammatory activity, improving patient comfort.

With canine otitis externa (OE), affecting up to 1 in 5 dogs visiting veterinary practicesⁱⁱ, the condition is a common frustration for dog owners. New research found more than half (55%) find it difficult to give ear medication twice daily to their dog and, for 86% of owners, reducing stress for their dog is a priority when treating ear infections.[ii]

Eliminating home treatments, Neptra’s launch will bring vets full control over treatment compliance and eliminate the uncertainty and stress of client administration.

Donna Tomlinson, Senior Brand Manager at Bayer said: “It’s not every day that you’re able to launch a solution that has the potential of Neptra^® to change treatment practices for the better and improve outcomes for dogs. Across the UK and Europe, our brilliant team at Bayer have put months of effort into this launch and developed an exciting marketing support package. Our veterinary business managers are already out on the road, ready to talk to you all about it.”

Neptra^® is available now to order as one simple SKU via your regular wholesaler or speak to your Bayer veterinary business manager. A single, 1ml dose in each affected ear treats dogs of all breeds.

To enquire about stocking Neptra^® please contact your local veterinary business manager.

Practice support materials are also available via www.vetcentre.bayer.co.uk

---

REFERENCES

[i] North American sales figures MAT Dec 2019
[ii] Dog Owner Compliance Evaluation, June 2019, n=2000 dog owners from FR/IT/ES/DE/NL/BE/UK/AU

*Claro (North American name) - is the same product as Neptra.
**Staphylococcus pseudintermedius and Malassezia pachydermatis